Healthcare professionals' views about how pregnant women can benefit from using a closed-loop system: Qualitative study.
closed-loop system
continuous glucose monitoring
healthcare professionals
pregnancy
qualitative research
technology
type 1 diabetes
Journal
Diabetic medicine : a journal of the British Diabetic Association
ISSN: 1464-5491
Titre abrégé: Diabet Med
Pays: England
ID NLM: 8500858
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
02
02
2023
received:
22
08
2022
accepted:
14
02
2023
medline:
13
4
2023
pubmed:
23
2
2023
entrez:
22
2
2023
Statut:
ppublish
Résumé
Interest is growing in how closed-loop systems can support attainment of within-target glucose levels amongst pregnant women with type 1 diabetes. We explored healthcare professionals' views about how, and why, pregnant women benefitted from using the CamAPS FX system during the AiDAPT trial. We interviewed 19 healthcare professionals who supported women using closed-loop during the trial. Our analysis focused on identifying descriptive and analytical themes relevant to clinical practice. Healthcare professionals highlighted clinical and quality-of-life benefits to using closed-loop in pregnancy; albeit, they attributed some of these to the continuous glucose monitoring component. They emphasised that the closed-loop was not a panacea and that, to gain maximum benefit, an effective collaboration between themselves, the woman and the closed-loop was needed. Optimal performance of the technology, as they further noted, also required women to interact with the system sufficiently, but not excessively; a requirement that they felt some women had found challenging. Even where healthcare professionals felt that this balance was not achieved, they suggested that women had still benefitted from using the system. Healthcare professionals reported difficulties predicting how specific women would engage with the technology. In light of their trial experiences, healthcare professionals favoured an inclusive approach to closed-loop rollout in routine clinical care. Healthcare professionals recommended that closed-loop systems be offered to all pregnant women with type 1 diabetes in the future. Presenting closed-loop systems to pregnant women and healthcare teams as one pillar of a three-party collaboration may help promote optimal use.
Sections du résumé
BACKGROUND
Interest is growing in how closed-loop systems can support attainment of within-target glucose levels amongst pregnant women with type 1 diabetes. We explored healthcare professionals' views about how, and why, pregnant women benefitted from using the CamAPS FX system during the AiDAPT trial.
METHODS
We interviewed 19 healthcare professionals who supported women using closed-loop during the trial. Our analysis focused on identifying descriptive and analytical themes relevant to clinical practice.
RESULTS
Healthcare professionals highlighted clinical and quality-of-life benefits to using closed-loop in pregnancy; albeit, they attributed some of these to the continuous glucose monitoring component. They emphasised that the closed-loop was not a panacea and that, to gain maximum benefit, an effective collaboration between themselves, the woman and the closed-loop was needed. Optimal performance of the technology, as they further noted, also required women to interact with the system sufficiently, but not excessively; a requirement that they felt some women had found challenging. Even where healthcare professionals felt that this balance was not achieved, they suggested that women had still benefitted from using the system. Healthcare professionals reported difficulties predicting how specific women would engage with the technology. In light of their trial experiences, healthcare professionals favoured an inclusive approach to closed-loop rollout in routine clinical care.
CONCLUSIONS
Healthcare professionals recommended that closed-loop systems be offered to all pregnant women with type 1 diabetes in the future. Presenting closed-loop systems to pregnant women and healthcare teams as one pillar of a three-party collaboration may help promote optimal use.
Substances chimiques
Blood Glucose
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15072Subventions
Organisme : British Heart Foundation
ID : RE/18/5/34216
Pays : United Kingdom
Informations de copyright
© 2023 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
Références
BMC Endocr Disord. 2018 Feb 20;18(1):12
pubmed: 29458348
Diabetes Res Clin Pract. 2022 May;187:109877
pubmed: 35469973
Diabet Med. 2020 Jun;37(6):1030-1037
pubmed: 31989684
Diabetes Technol Ther. 2019 Mar;21(3):119-127
pubmed: 30720338
Diabetologia. 2017 Sep;60(9):1668-1677
pubmed: 28597075
BMJ. 2018 Apr 18;361:k1310
pubmed: 29669716
BMJ. 2008 Sep 25;337:a1680
pubmed: 18818254
Diabet Med. 2023 May;40(5):e15072
pubmed: 36807582
BMC Pregnancy Childbirth. 2022 Apr 5;22(1):282
pubmed: 35382796
Diabetes Care. 2011 Feb;34(2):406-11
pubmed: 21216859
Diabet Med. 2016 Feb;33(2):243-51
pubmed: 26248590
Diabetologia. 2010 Mar;53(3):446-51
pubmed: 20013109
Diabetes Technol Ther. 2020 Jun;22(6):468-475
pubmed: 32048877
Lancet. 2017 Nov 25;390(10110):2347-2359
pubmed: 28923465
Diabet Med. 2018 Apr;35(4):409-418
pubmed: 29247556
N Engl J Med. 2016 Aug 18;375(7):644-54
pubmed: 27532830
Diabet Med. 2019 Jun;36(6):753-760
pubmed: 30575114
Lancet Diabetes Endocrinol. 2018 Jan;6(1):15
pubmed: 29273166
Diabetes Care. 2011 Dec;34(12):2527-9
pubmed: 22011408
Diabetes Care. 2018 Jul;41(7):1391-1399
pubmed: 29535135
J Diabetes Sci Technol. 2018 Nov;12(6):1125-1131
pubmed: 30288999
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
Lancet Diabetes Endocrinol. 2017 Jul;5(7):501-512
pubmed: 28533136
Diabetes Technol Ther. 2023 Apr;25(4):260-269
pubmed: 36662589
J Diabetes Sci Technol. 2016 Aug 22;10(5):1115-21
pubmed: 27417141
Chronic Illn. 2022 Dec;18(4):742-756
pubmed: 33472409
Diabetes Care. 2019 Aug;42(8):1593-1603
pubmed: 31177185